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A B S T R A C T
Purpose
Vandetanib is an oral once-daily tyrosine kinase inhibitor with activity against vascular endothelial
growth factor receptor 2 and epidermal growth factor receptor. Vandetanib in combination with
docetaxel was assessed in patients with advanced urothelial cancer (UC) who progressed on prior
platinum-based chemotherapy.
Patients and Methods
The primary objective was to determine whether vandetanib 100 mg plus docetaxel 75 mg/m2
intravenously every 21 days prolonged progression-free survival (PFS) versus placebo plus
docetaxel. The study was designed to detect a 60% improvement in median PFS with 80% power
and one-sided  at 5%. Patients receiving docetaxel plus placebo had the option to cross over to
single-agent vandetanib at progression. Overall survival (OS), overall response rate (ORR), and
safety were secondary objectives.
Results
In all, 142 patients were randomly assigned and received at least one dose of therapy. Median PFS
was 2.56 months for the docetaxel plus vandetanib arm versus 1.58 months for the docetaxel plus
placebo arm, and the hazard ratio for PFS was 1.02 (95% CI, 0.69 to 1.49; P  .9). ORR and OS
were not different between both arms. Grade 3 or higher toxicities were more commonly seen in
the docetaxel plus vandetanib arm and included rash/photosensitivity (11% v 0%) and diarrhea
(7% v 0%). Among 37 patients who crossed over to single-agent vandetanib, ORR was 3% and
OS was 5.2 months.
Conclusion
In this platinum-pretreated population of advanced UC, the addition of vandetanib to docetaxel did
not result in a significant improvement in PFS, ORR, or OS. The toxicity of vandetanib plus
docetaxel was greater than that for vendetanib plus placebo. Single-agent vandetanib activity
was minimal.
J Clin Oncol 30:507-512. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Urothelial carcinoma (UC) is the fifth most com-
mon malignancy in the United States and accounts
for more than 13,000 deaths yearly.1 Few advances
have been made in the treatment of advanced UC in
the last decade. Standard of care in the United States
consists of a platinum-based therapy (eg, gemcit-
abine plus cisplatin or methotrexate, cisplatin, doxo-
rubicin and vinblastine).2 Once patients progress
through one of these regimens, there is no standard
second line-therapy.3 In the second-line setting,
many agents, including docetaxel,4 paclitaxel,5,6 and
pemetrexed,7,8 demonstrate response rates between
10% and 20%, yet no drug has been proven to pro-
long overall survival (OS). Vinflunine, a novel syn-
thetic vinca alkaloid, did not confer an OS advantage
over placebo in an intent-to-treat population and is
not approved in the United States.9 Because of this
lack of a standard second-line agent, practice pat-
terns differ, although taxanes are the most com-
monly used agents.10
An appealing therapy strategy for the treatment
of advanced UC is the addition of targeted agents to
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chemotherapy.11,12 Several targets in UC may be biologically relevant,
including vascular endothelial growth factor receptor (VEGFR) and
epidermal growth factor receptor (EGFR).12 VEGFR- and EGFR-
directed therapy have proven clinically useful in multiple tumor types,
usually in combination with chemotherapy. Preclinically, combina-
tion therapy with a taxane and DC101, a VEGFR antibody,13 or cetux-
imab, an EGFR antibody,14 caused significant regression of human
UC growing in nude mice, with the combination being more active
than either agent alone.
Vandetanib (AstraZeneca, Macclesfield, United Kingdom) is
an oral once-daily selective tyrosine kinase inhibitor of key signal-
ing pathways in cancer, including VEGFR-2 (median inhibition
concentration [IC50], 0.04 mol/L) and EGFR (IC50, 0.5 mol/L).
Early clinical trials showed that this agent alone or in combination
with docetaxel has an acceptable adverse effect profile and produced
tumor responses.15 Randomized studies in non–small-cell lung cancer
showed that the addition of vandetanib to docetaxel resulted in a
significant prolongation of progression-free survival (PFS) compared
with docetaxel alone. Vandetanib is currently approved by the US
Food and Drug Administration (FDA) for the treatment of advanced
medullary thyroid cancer.16,17
On the basis of the above data and the potential importance of
VEGFR and EGFR in UC, a randomized phase II study of docetaxel
with vandetanib or placebo was initiated. This trial is a multicenter
study in patients with advanced UC who have experienced progres-
sion after a platinum-containing regimen. Our primary hypothesis




Eligible patients required histologically or cytologically confirmed locally
advanced or metastatic UC, progression of disease documented by the inves-
tigator after platinum-containing chemotherapy, age  18 years, and Eastern
Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
Prior docetaxel and prior VEGF-targeted therapies were not allowed. The
study did not initially allow prior paclitaxel, but because of an initial slow
accrual rate, the study was amended to allow it. Overall, up to three systemic
therapies were allowed (given in the metastatic and/or within 2 years of adju-
vant or neoadjuvant settings). Patients were required to have adequate hema-
tologic, hepatic, and renal (calculated creatinine clearance  30 mL/min by the
Cockcroft-Gault formula) function. Patients with uncontrolled arrhythmias,
QTc  480 ms on screening ECG, serum calcium or magnesium below lower
limits of normal, and serum potassium less than 4 mmol/L (despite supple-
mentation) were excluded. Patients with brain metastasis could be included if
they were treated more than 4 weeks before enrollment, were asymptomatic,
and had a stable post-treatment brain magnetic resonance imaging scan. The
trial was approved by all relevant institutional ethical committees and con-
ducted in accordance with the Declaration of Helsinki and Good Clinical
Practice.18 Each patient provided written informed consent.
Study Design and Treatment Plan
This was a randomized, multicenter, double-blind, placebo-controlled,
investigator-initiated phase II trial. Patients were randomly assigned 1:1 to
vandetanib plus docetaxel or placebo plus docetaxel. Randomized treatment
codes were generated by the Dana-Farber Cancer Institute’s Quality Assurance
Office for Clinical Trials (QACT) office. A computerized random number
generator was used to produce permuted blocks of treatment codes.19 The
number of possible permutations depended on the block size and number of
individual treatments and was undisclosed to investigators. A string of per-
muted blocks was generated for each stratification factor combination, and
treatment assignments were consumed sequentially. Patients were stratified
on the basis of measurable disease at presentation (v evaluable-only disease),
ECOG PS of 0 and no visceral metastasis (v either ECOG PS of 1 or visceral
metastasis or both), and number of prior systemic chemotherapy regimens
(one v  one regimen). Patients on both arms underwent 21-day dosing cycles
with docetaxel 75 mg/m2 via 1-hour infusion on day 1 and dexamethasone 8
mg at about 12, 3, and 1 hour before docetaxel. Vandetanib and matching
placebo were given as 100-mg tablets orally once daily. Patients receiving
placebo tablets were assigned to take them on the same schedule as the patients
receiving vandetanib. Treatment was administered until documented progres-
sion, unacceptable toxicity, or patient refusal. Once eligibility for crossover
treatment was documented, the blind was broken and, if the patient was on the
placebo arm and met crossover eligibility, single-agent vandetanib was offered.
Clinical Assessment
Preregistration assessments included a detailed medical history, physical
examination, and imaging for tumor assessment. Imaging studies were ob-
tained every 6 weeks for the first two cycles and every 9 weeks thereafter.
Investigators assessed efficacy by using Response Evaluation Criteria in Solid
Tumors (RECIST 1.0).20 The maximum percentage of tumor shrinkage on
study was also recorded. Physical examination, ECOG PS, and vital signs were
assessed on day 1 of each cycle. ECGs were obtained at baseline and on day 1 of
cycles 1 to 5, and then every four cycles. A CBC and a biochemical assessment
with electrolytes were obtained on day 1 of every cycle. Blood specimens and
archival tumor tissue for correlative studies were collected at baseline.
Toxicity was assessed throughout the treatment period and before each
administration according to the National Cancer Institute’s Common Termi-
nology Criteria for Adverse Events (CTCAE) version 3.0. Docetaxel and ther-
apy were withheld for any CTCAE grade 3 or 4 toxicities (other than alopecia,
anemia, and fatigue) until they resolved to grade  1. If the toxicity was felt to
be related to study treatment, therapy was reduced one dose level. Docetaxel
dose reductions were dose level 1 (60 mg/m2) and dose level 2 (48 mg/m2).
For vandetanib and placebo, there was one dose reduction at 100 mg every
other day. Patients completed a diary to report compliance with study drug
and premedications.
Statistical Methods
The primary end point of the trial was PFS, which was defined as the time
between random assignment and documented progression per RECIST crite-
ria or death. Patients alive and without evidence of progression were censored
on the date of last evaluation. The study was designed with 80% power to
detect a 60% improvement in median PFS from 4.5 to 7.2 months: the do-
cetaxel plus vandetanib and/or docetaxel plus placebo hazard ratio (HR) was
0.625 with the addition of vandetanib, given a one-sided overall significance
level of 5% and 140 randomly assigned patients. This assumes exponential
distribution of events, accrual of 1.75 patients per week (seven to eight patients
per month) for 78 weeks, with 34 weeks of additional follow-up (112 weeks
total) and full information on 118 PFS events. Group-sequential design meth-
ods were used with a truncated O’Brien-Fleming upper bound for early rejec-
tion of the null hypothesis of no treatment difference by using a log-rank test.
One planned interim analysis occurred at 40% (49 of 118) PFS events. Second-
ary end points included overall response rate (ORR) by RECIST, disease
control rate (DCR: ORR plus stable disease), OS, safety, and efficacy of single-
agent vandetanib in the crossover portion of the study. OS was measured from
date of random assignment until date of death.
Time to events distributions were estimated by the Kaplan-Meier
method. The log-rank test was used to compare time-to-event distributions.
Cox proportional hazards regression was used to estimate the treatment HR
(docetaxel plus vandetanib and/or docetaxel plus placebo) in unadjusted and
adjusted models. Multiple regression models were undertaken to estimate the
effect of treatment on survival taking into account several prespecified clinical
and/or laboratory prognostic factors: age, ECOG PS, visceral and liver metas-
tases, hemoglobin (Hb), number of prior systemic therapies, prior cystectomy,
prior paclitaxel, and the recently identified Bellmunt prognostic model.21
Two-sided Fisher’s exact test was used to compare toxicity and response rates
by treatment arm. Patients who were randomly assigned but never received
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any treatment dose were allowed to be replaced. Analyses for safety and efficacy
used results from patients who received at least one dose of therapy.
RESULTS
In all, 149 patients (docetaxel plus vandetanib, n  74; docetaxel plus
placebo, n  75) were enrolled and randomly assigned between Feb-
ruary 2007 and May 2010 at 16 active sites in the United States. In total,
142 patients received at least one dose of treatment. Completed diaries
were returned at more than 90% of visits. Seven patients were ran-
domly assigned but were not able to receive any study drug for various
reasons. Figure 1 shows the study profile. Median follow-up for the
patients still alive is 7.1 months.
Demographics
Baseline demographics were well balanced between both arms
(Table 1). However, there was a greater proportion of patients with Hb
less than 10g/dL on the docetaxel plus vandetanib arm (P  .035).
Primary End Point: PFS
Median PFS for the docetaxel plus vandetanib combination was
2.56 months versus 1.58 months for the docetaxel plus placebo com-
bination (HR, 1.02; 95% CI, 0.69 to 1.49) with no statistical signifi-
cance (P  .939; Fig 2). Similarly the 3-month PFS rate was not
different: 36% in the docetaxel plus vandetanib arm versus 40% in the
docetaxel plus placebo arm.
Secondary End Points and Subgroup Analysis
Median OS for the docetaxel plus vandetanib arm was 5.85
months versus 7.03 months for the docetaxel plus placebo combina-
tion (HR, 1.21; 95% CI, 0.81 to 1.79; P  .347; Fig 3). ORR and DCR
were also similar between study arm versus control arm (ORR: 7%
[eight of 72] v 11% [five of 70], respectively; P  .56; DCR: 51% [36 of
70] v 42% [30 of 72], respectively; P  .31). One patient achieved a
complete response on the docetaxel plus vandetanib arm. Overall,
41% of patients experienced some form of tumor shrinkage on the
docetaxel plus vandetanib arm (median, 10.8%) versus 37% on the
docetaxel plus placebo arm (median, 16.3%).
Assessed for eligibility 
(N = 193)
Patients randomly assigned 
(n = 149)
Docetaxel + vandetanib
   Received allocated intervention





   Received allocated intervention
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   Refused to participate/consent





Fig 1. CONSORT diagram. (*) Reasons
include new brain metastases; failure to
meet eligibility requirements on day 1
because of electrolyte abnormalities; and
consent withdrawal, failure to come to the
appointment, or use of an alternative reg-
imen on the first day of the protocol.









No. % No. %
Age  65 years 38 54.3 33 45.8
Male sex 48 68.6 49 68.1
ECOG PS 1 30 42.9 38 52.8
Visceral metastases 47 67.1 46 63.9
Liver metastases 23 32.9 27 37.5
PS 1 and/or visceral metastases 58 82.9 55 76.4
No. of prior systemic therapies
 1 34 48.6 28 38.9
 2 12 17.1 10 13.9
Prior cystectomy 32 46.4 36 50
Prior radiation 17 24.3 15 20.8
Prior paclitaxel 13 18.6 8 11.1
Hemoglobin  10g/dL 15 21.4 6 8.5
Bellmunt risk score  021 46 65.7 49 69
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, perfor-
mance status.
P  .05.
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Exploratory analyses were conducted in several subgroups to
detect whether there is any preferential activity for the docetaxel plus
vandetanib group over docetaxel plus placebo in terms of PFS or OS.
No differences were found to favor the study group arm over the
control arm for both PFS and OS. For example, patients with one and
more than one prior systemic therapies had a PFS of 1.54 and 1.58
months on the docetaxel plus placebo arm versus 2.53 and 2.66
months on the docetaxel plus vandetanib arm, respectively. OS was
similar in both arms (6.8 months) in patients with more than one
prior systemic therapy; in those with one prior therapy, OS was 7.39
months in the docetaxel plus placebo arm versus 5.62 months in the
docetaxel plus vandetanib arm (Appendix Figs A1 and A2, on-
line only).
Study Drug Exposure and Tolerability
Approximately 74% of patients completed four cycles of treat-
ment on each arm. The median treatment duration for patients on
study was two cycles, and the mean was 3.9 cycles. As of the December
1, 2010, cutoff for the study analysis, five patients were still receiving
treatment. Their median treatment duration was 14 cycles (range, 11
to 24 cycles). All-grade and high-grade toxicities were 66% and 60% in
the docetaxel plus vandetanib arm and 44% and 36% in the docetaxel
plus placebo arm, respectively (P  .012 for all-grade and P  .007 for
high-grade toxicities). However, grade 4 toxicities were not different
between both arms (14.3% for the docetaxel plus vandetanib arm and
11.1% for the docetaxel plus placebo arm). Nonhematologic adverse
effects were more common in the vandetanib plus docetaxel arm, with
the most frequent being diarrhea and rash/photosensitivity. Table 2
provides the most common treatment-related adverse events and
hematologic toxicities for both arms. Only one patient’s death was
possibly related to the study drug in the vandetanib plus docetaxel arm
(pulmonary infection).
Single-Agent Activity and Toxicity
Thirty-seven patients who progressed on the randomized por-
tion of the trial were found to be on the docetaxel plus placebo arm on
unblinding, and they met the eligibility criteria to cross over to vande-
tanib. Overall, one patient who crossed over had a partial response
corresponding to an ORR of 2.8%. Stable disease was seen in five
patients (13.5%). Median OS from starting vandetanib treatment was
5.2 months. Thirty percent of patients experienced all-grade toxicities,
with 16% being grade 3. Fatigue (all-grade: five of 37 [13.5%]; high-
grade: two of 37 [5.4%]) was the most common toxicity seen with
single-agent vandetanib, followed by dyspnea (all-grade: three of 37
[8.1%]; high-grade: two of 37 [5.4%]).
Prognostic Factors
To identify prognostic factors associated with OS, we performed
a multivariable analysis of prespecified clinical and laboratory fac-
tors.21,22 In addition, we assessed the performance of the prognostic
model published by Bellmunt et al21 in patients for whom prior



















No. % No. % No. % No. %
Hematologic 15 21 13 19 15 21 14 19
Anemia 4 6 3 4 2 3 1 1
Neutropenia 10 14 10 14 10 14 10 14
Nonhematologic 40 57 35 50 26 36 18 25
Diarrhea 11 16 5 7 0 0 0 0
Fatigue 15 21 6 9 10 14 4 6
Rash/photosensitivity 9 13 8 11 2 3 0 0
Infections 5 7 3 4 5 7 4 6
Neuropathy 4 6 2 3 2 3 0 0
Electrolyte
abnormalities 10 14 7 10 4 6 4 6
P  .05 for both all-grade and high-grade toxicities.
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Fig 3. Overall survival (months). D, docetaxel; HR, hazard ratio; P, placebo;
V, vandetanib.
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platinum-based therapies failed. This model includes three adverse
prognostic factors: Hb less than 10 g/dL, the presence of liver metas-
tasis, and ECOG PS  0.21 Patients were dichotomized into two
groups: one group with zero risk factors and one group with one or
more risk factors, as detailed in Table 1. In our analysis, each of the
three factors identified by Bellmunt et al21 were significant prognostic
factors strongly associated with the risk of death, with the lowest HR
seen for the Bellmunt risk score model (HR, 0.30; 95% CI, 0.18 to 0.48;
P  .001). In addition, prior cystectomy was also found to be associ-
ated with a better OS (Table 3).
DISCUSSION
This randomized multicenter study of docetaxel plus placebo versus
docetaxel plus vandetanib showed that the addition of vandetanib (a
dual inhibitor of VEGFR and EGFR) to docetaxel did not result in
clinical benefit. PFS and OS in the whole cohort were relatively short.
The vandetanib plus docetaxel arm had more patients with Hb less
than 10 g/dL (13% difference), a known adverse factor, but this im-
balance that favored the placebo group is unlikely to have biased the
results, since the rest of the patients’ characteristics were balanced
between both arms. We also did not find any advantage (in term of
PFS or OS) of adding vandetanib to docetaxel when we looked at
several subgroups stratified by number of prior lines of systemic ther-
apies, use of prior paclitaxel, and adverse prognostic factors. Further-
more, toxicities (both all-grade and high-grade) were greater, despite
the fact that they were manageable with only one death possibly
attributed to study drug.
Despite their minimal activity, taxanes are the most commonly
used salvage agents in UC. A phase III study of vinflunine (a novel
vinca-alkaloid)9 in pretreated patients with UC showed an OS of 6.9
months versus 4.6 months in patients who received best supportive
care (P .28). The OS in the vinflunine study is quite similar to the OS
in our study, suggesting that salvage chemotherapy has little effect on
the natural history of this disease.
The median OS in our study was less than 7 months, inferior
to what was reported (OS, 9 months) more than 10 years ago in a
single-arm phase II study of docetaxel.4 Although our study is
more recent, our patient population was heavily pretreated: 43% of
patients received two or more systemic therapies, and 15% had
already received another taxane (paclitaxel). In the older study,
only one prior therapy was allowed, and patients with prior expo-
sure to paclitaxel were excluded. Therefore, one possible explana-
tion for poor activity of docetaxel in our study is that the previously
treated patients who were selected had disease that was too ad-
vanced to detect any activity.
Despite the encouraging preclinical data with agents targeting
the EGF or the VEGF axis in bladder cancer, early trials of single-
agent EGFR or VEGFR inhibitors have yielded poor results. Al-
though gefitinib has shown activity against two bladder cell lines in
vitro23 and resulted in a decrease in DNA synthesis in bladder
cancer cell lines,24 phase II studies of single-agent gefitinib and
lapatinib in platinum-refractory patients with UC did not show
any meaningful activity.25,26 Similarly, single-agent phase II trials
of VEGFR inhibitors did not show convincing results. In one trial,
sorafenib did not show any responses in 27 treated patients.27
Conversely, sunitinib showed few responses in 77 patients who
were pretreated with platinum, with minor responses or stable
disease in 43% of patients.28 Nevertheless, OS was 6 months, in line
with several other trials of salvage chemotherapy.
Patients who crossed over to single-agent vandetanib also rarely
responded to therapy, and their survival was only 5.2 months. The
patients treated with single-agent vandetanib (n  37) had to have
progressed through at least one platinum-based therapy and then have
experienced treatment failure with a taxane (docetaxel); thus, they
were an even more refractory population.
The results of the multivariate Cox regression model con-
firmed the prognostic value of several factors on OS, specifically in
our population of patients who had platinum-based pretreatment.
We found that a prior cystectomy confers better OS, likely a reflec-
tion of the fact that such patients presented with organ-confined
and less aggressive disease amenable to cystectomy. We also exter-
nally validated the Bellmunt model itself21 as the strongest predic-
tor of OS (HR, 0.3) in a platinum-refractory population. This
model, derived from patients treated with vinflunine, is now more
generalizable and applicable to patients treated with taxanes. It can
be used for counseling patients and future stratification in clinical
trials of novel agents.
Our study has several strengths: It is a randomized, placebo-
controlled study that represents the second largest trial of salvage
chemotherapy in bladder cancer and the largest trial with EGFR
and VEGFR inhibitors. Nevertheless, it remains a phase II study,
able to detect only large differences in clinical outcomes. Nonethe-
less, it is unlikely that vandetanib offers any benefit to a similar
population of patients. Future trials with vandetanib based on
preselected biomarkers or less heavily treated patients are potential
areas of investigation.
In conclusion, the addition of vandetanib (a dual EGFR and
VEGFR inhibitor) to docetaxel did not result in clinical benefit in a
population of patients with advanced UC who were previously treated
with platinum-based therapies. At this time, vandetanib cannot be
recommended for future studies in the salvage setting.
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9. Bellmunt J, Théodor C, Demkov T, et al:
Phase III trial of vinflunine plus best supportive care
compared with best supportive care alone after a
platinum-containing regimen in patients with ad-
vanced transitional cell carcinoma of the urothelial
tract. J Clin Oncol 27:4454-4461, 2009
10. Bellmunt J, Choueiri TK, Schutz FA, et al:
Randomized phase III trials of second-line chemo-
therapy in patients with advanced bladder cancer:
Progress and pitfalls. Ann Oncol 22:245-247, 2011
11. Abou-Jawde R, Choueiri T, Alemany C, et al:
An overview of targeted treatments in cancer. Clin
Ther 25:2121-2137, 2003
12. Mitra AP, Datar RH, Cote RJ: Molecular path-
ways in invasive bladder cancer: New insights into
mechanisms, progression, and target identification.
J Clin Oncol 24:5552-5564, 2006
13. Inoue K, Slaton JW, Davis DW, et al: Treat-
ment of human metastatic transitional cell carci-
noma of the bladder in a murine model with the
anti-vascular endothelial growth factor receptor
monoclonal antibody DC101 and paclitaxel. Clin Can-
cer Res 6:2635-2643, 2000
14. Inoue K, Slaton JW, Perrotte P, et al: Pacli-
taxel enhances the effects of the anti-epidermal
growth factor receptor monoclonal antibody Im-
Clone C225 in mice with metastatic human bladder
transitional cell carcinoma. Clin Cancer Res 6:4874-
4884, 2000
15. Morabito A, Piccirillo MC, Falasconi F, et al:
Vandetanib (ZD6474), a dual inhibitor of vascular
endothelial growth factor receptor (VEGFR) and
epidermal growth factor receptor (EGFR) tyrosine
kinases: Current status and future directions. Oncol-
ogist 14:378-390, 2009
16. Heymach JV, Johnson BE, Prager D, et al:
Randomized, placebo-controlled phase II study of
vandetanib plus docetaxel in previously treated non
small-cell lung cancer. J Clin Oncol 25:4270-4277,
2007
17. Herbst RS, Sun Y, Eberhardt WE, et al:
Vandetanib plus docetaxel versus docetaxel as
second-line treatment for patients with advanced
non-small-cell lung cancer (ZODIAC): A double-
blind, randomised, phase 3 trial. Lancet Oncol
11:619-626, 2010
18. World Medical Association: WMA Declaration
of Helsinki - Ethical Principles for Medical Research
Involving Human Subjects. http://www.wma.net/en/
30publications/10policies/b3/index.html
19. Zelen M: The randomization and stratification
of patients to clinical trials. J Chronic Dis 27:365-
375, 1974
20. Therasse P, Arbuck SG, Eisenhauer EA, et al:
New guidelines to evaluate the response to treat-
ment in solid tumors: European Organization for
Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Insti-
tute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Bellmunt J, Choueiri TK, Fougeray R, et al:
Prognostic factors in patients with advanced transi-
tional cell carcinoma of the urothelial tract experi-
encing treatment failure with platinum-containing
regimens. J Clin Oncol 28:1850-1855, 2010
22. Bajorin DF, Dodd PM, Mazumdar M, et al:
Long-term survival in metastatic transitional-cell car-
cinoma and prognostic factors predicting outcome
of therapy. J Clin Oncol 17:3173-3181, 1999
23. Nutt JE, Lazarowicz HP, Mellon JK, et al:
Gefitinib (‘Iressa’, ZD1839) inhibits the growth re-
sponse of bladder tumour cell lines to epidermal
growth factor and induces TIMP2. Br J Cancer
90:1679-1685, 2004
24. Shrader M, Pino MS, Brown G, et al: Molec-
ular correlates of gefitinib responsiveness in human
bladder cancer cells. Mol Cancer Ther 6:277-285,
2007
25. Petrylak DP, Tangen CM, Van Veldhuizen PJ
Jr, et al: Results of the Southwest Oncology Group
phase II evaluation (study S0031) of ZD1839 for
advanced transitional cell carcinoma of the urothe-
lium. BJU Int 105:317-321, 2010
26. Wülfing C, Machiels JP, Richel DJ, et al: A
single-arm, multicenter, open-label phase 2 study of
lapatinib as the second-line treatment of patients
with locally advanced or metastatic transitional cell
carcinoma. Cancer 115:2881-2890, 2009
27. Dreicer R, Li H, Stein M, et al: Phase 2 trial of
sorafenib in patients with advanced urothelial can-
cer: A trial of the Eastern Cooperative Oncology
Group. Cancer 115:4090-4095, 2009
28. Gallagher DJ, Milowsky MI, Gerst SR, et al:
Phase II study of sunitinib in patients with meta-




512 © 2011 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
